Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Role of Dopamine Transporter Scan (DaTscan) imaging in the Evaluation of Parkinsonism: Experience from a Tertiary Care Center
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
162
Describe real-life value of DaTscan in a Movement Disorder Center for improving diagnosis and management.
DaTscan uses a radiopharmaceutical marker of the striatal dopamine transporter to unmask striatonigral degeneration for diagnosis of neurodegenerative parkinsonism syndromes. It has been available since 2011. Initially approved to eliminate cases of essential tremor, its use has evolved to clarify other mimics of neurodegenerative parkinsonism syndromes. 

A single center retrospective chart review at University of Nebraska Medical Center (UNMC) Movement Disorders Clinic including five Movement Disorders Specialists (MDS) from 2013-2019.

Our 190 patients had a slight male predominance (n=115, 60.5%) and average age of 67.6 years (range 33-94). Mean Unified Parkinson Disease Rating Scale (UPDRS) Motor Score was 28.76 (range 3-75, median 28). Most patients had resting tremor (n=105, 55.26%). Mean duration of symptoms before DaTscan was 6.28 years (range 0-43, median 4).

The most common reasons for DaTscan was drug-induced parkinsonism (n=38, 20%). Others included nonspecific parkinsonism (n=37,19.47%), vascular parkinsonism (n=13,6.8%), essential tremor (n=19,10%) and dystonia(n=19,10%).

About half of the patients with DaTscans showed a positive scan (n=99, 52.1%) indicative of neurodegenerative Parkinsonism syndrome. Only one patient had an equivocal result and all others were normal. DaTscan led to treatment change in most patients (n=118, 62.1%).

DaTscan was of proven value for correctly managing drug-induced parkinsonism, vascular parkinsonism, and rare situations including dopa-responsive dystonia, and patients with comorbid brain diseases or injury. In our practice DaTscan was positive in half of the cases, and guided management in most of them.
Authors/Disclosures
Deepmala Nandanwar, MD
PRESENTER
Dr. Nandanwar has nothing to disclose.
Sarah J. Doss, MD (Bryan Health Kearney) Dr. Doss has nothing to disclose.
Sarah J. Doss, MD (Bryan Health Kearney) Dr. Doss has nothing to disclose.
Daniel A. Crespo, MD (Bryan) Dr. Crespo has nothing to disclose.
Kiley Cameron, MD (Medical College of Wisconsin) Dr. Cameron has nothing to disclose.
Diego Torres-Russotto, MD, FÂé¶¹´«Ã½Ó³»­ (Miami Neuroscience Institute - Baptist Health South Florida) Dr. Torres-Russotto has received personal compensation for serving as an employee of Movement Disorders Consulting, Inc. The institution of Dr. Torres-Russotto has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. The institution of Dr. Torres-Russotto has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. The institution of Dr. Torres-Russotto has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Revance. The institution of Dr. Torres-Russotto has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anneal. Dr. Torres-Russotto has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for IPSEN. Dr. Torres-Russotto has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Torres-Russotto has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AbbVie. The institution of Dr. Torres-Russotto has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurocrine. Dr. Torres-Russotto has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Your Nest Asset Solutions, LLC. Dr. Torres-Russotto has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Bright Future Asset Solutions, LLC.
John M. Bertoni, MD, PhD, FÂé¶¹´«Ã½Ó³»­ (University of Nebraska Medical Center) Dr. Bertoni has nothing to disclose.
Danish Bhatti, MD, FÂé¶¹´«Ã½Ó³»­ (University of Central Florida College of Medicine) Dr. Bhatti has nothing to disclose.